Morningstar

Lantern Pharma Reports Additional Positive LP-184 Phase 1a Results Showing Durable Disease Control in Heavily Pre-Treated Advanced Cancer Patients as Company Advances Precision ...

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical-stage biotechnology company using artificial intelligence and genomics to transform oncology drug development, announced additional details and clinical ...
Business Wire

Lantern Pharma Announces First Patient Dosed in the Phase 1 Study for LP-184 in Advanced Solid Tumors

DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary AI and machine ...
Seeking Alpha

Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)

The FDA has cleared the investigational new drug (IND) application of LP-184 in triple negative breast cancer (TNBC) treatment – a novel small molecule advanced and developed with Lantern’s AI ...
La Grande Observer

Breakthrough! Exciting interim Phase II Data of LP-003 in CSU released by Longbio at AAAAI 2025

SAN DIEGO, March 2, 2025 /PRNewswire/ — Longbio Pharma (Suzhou) Co., Ltd. (referred to as “Longbio”), a leading biotech company dedicated to developing innovative biologic treatments for allergy, ...
Nasdaq

Lantern Pharma’s LP-184 Phase 1a Clinical Trial Achieves All Primary Endpoints with Robust Safety Profile and Promising Antitumor Activity in Multiple Advanced Solid Tumors

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), a leading artificial intelligence (AI)-driven oncology company leveraging its proprietary RADR® platform to accelerate targeted cancer ...